The GSPT2 Knockout NCI-H1975 Polyclonal Cells product is a heterogeneous population of NCI-H1975 human lung adenocarcinoma cells in which the GSPT2 gene has been disrupted by CRISPR/Cas9-mediated genome editing. As a polyclonal knockout pool, it provides a versatile loss-of-function model to study GSPT2 functions in translation termination and nonsense-mediated mRNA decay (NMD) within a disease-relevant context, avoiding the selection biases of single-cell clones.
The NCI-H1975 parental line is derived from a female non-small cell lung cancer (NSCLC) patient and carries EGFR L858R and T790M mutations. These mutations make it a widely used model for EGFR-targeted therapy resistance, particularly for investigating acquired resistance to third-generation tyrosine kinase inhibitors. Its epithelial adenocarcinoma phenotype offers a physiologically relevant background for evaluating tumor cell biology.
GSPT2 encodes ERF3B, a translational GTPase that cooperates with eRF1 to recognize stop codons and trigger polypeptide chain release, terminating protein synthesis. Beyond termination, ERF3B participates in NMD by interacting with UPF1, SMG1, SMG6, and the ribosome to degrade mRNAs with premature stop codons. GSPT2 expression is regulated by the oncogenic transcription factor MYC and the mTORC1 signaling pathway, while it functionally delivers eRF1 to ribosomes and connects to the NMD machinery, including PABPC1 and the SURF complex components.
In the NCI-H1975 EGFR-mutant lung adenocarcinoma background, GSPT2 knockout likely disrupts translation termination fidelity and impairs NMD, leading to elevated stop-codon readthrough and accumulation of aberrant proteins. This may compromise cell viability and alter sensitivity to EGFR inhibitors, providing a system to elucidate how translational control and mRNA surveillance influence drug resistance and oncogenic growth in NSCLC.
This polyclonal knockout model supports diverse applications: Western blotting and RT-qPCR to verify GSPT2 depletion and NMD target changes; flow cytometry and viability assays for cell cycle and survival analysis; translation termination reporter assays to quantify readthrough; and co-immunoprecipitation to examine interactions with eRF1, ribosomes, or NMD factors. Such studies can reveal GSPT2??s contributions to NSCLC pathogenesis and identify vulnerabilities in the translation machinery. For further details, contact Ascent Research.
